MariMed (OTCMKTS:MRMD – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01), Zacks reports. MariMed had a negative return on equity of 10.71% and a negative net margin of 9.13%.
MariMed Price Performance
MariMed stock traded up $0.00 during trading hours on Wednesday, reaching $0.07. 1,419,244 shares of the stock were exchanged, compared to its average volume of 582,543. The company has a current ratio of 0.92, a quick ratio of 0.34 and a debt-to-equity ratio of 1.78. MariMed has a twelve month low of $0.04 and a twelve month high of $0.16. The company has a market cap of $29.82 million, a P/E ratio of -1.85 and a beta of 1.54. The stock has a 50 day moving average of $0.07 and a two-hundred day moving average of $0.07.
About MariMed
MariMed, Inc. is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products. MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.
Read More
- Five stocks we like better than MariMed
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
